Topical Ruxolitinib for the Treatment of Vitiligo
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Tufts Medical Center
- Study ID
- NCT02809976
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ruxolitinib 1.5% Phosphate Cream — DRUGtwice daily topical application of Ruxolitinib 1.5% Phosphate Cream beginning at baseline and ending at week 20
Study Details
The purpose of this study is to determine if topical ruxolitinib 1.5% will provide repigmentation in vitiligo lesions.
Key Dates
- Start date
- Jan 31, 2016
- Status verified
- Aug 2020
- Primary completion
- Jan 31, 2017
- Completion
- Feb 28, 2017
Study Design
- Enrollment
- 11 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Ruxolitinib 1.5% phosphate creamRuxolitinib 1.5% phosphate cream twice daily to vitiligo patches.
Primary Outcome Measure
Percent Change in Vitiligo Area Severity Index (VASI) Score From Baseline to Week 20 [ Time Frame: Baseline to Week 20 ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Tufts Medical Center | Boston | Massachusetts | 02111 | - |
Find similar trials in Boston, MA
By research site
Related Studies
- A Study of LY4005130 in Adult Participants With Non-Segmental VitiligoPHASE2 · Recruiting · Eli Lilly and Company · Phoenix, Arizona
- The Gut and Skin Microbiome in Vitiligo Disease ProgressionRecruiting · Northwestern University · Chicago, Illinois